Difference between revisions of "Myelofibrosis"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 3: Line 3:
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
 
Is there a regimen missing from this list?  Would you like to share a different dosage/schedule or an additional reference for a regimen?  Have you noticed an error?  Do you have an idea that will help the site grow to better meet your needs and the needs of many others?  You are [[How_to_contribute|invited to contribute to the site]].
  
−
{{TOC limit|limit=3}}
+
{{TOC limit|limit=2}}
  
−
=Untreated=
+
==Ruxolitinib (Jakafi)==
  
−
==Ruxolitinib (Jakafi)==
+
===Regimen, Verstovsek, et al. 2010; Harrison, et al. 2012 (COMFORT-II); Verstovsek, et al. 2012 (COMFORT-I)===
 +
COMFORT: '''<u>CO</u>'''ntrolled '''<u>M</u>'''yelo'''<u>F</u>'''ibrosis Study with '''<u>OR</u>'''al JAK Inhibitor '''<u>T</u>'''reatment
  
−
===Regimen===
 
 
Level of Evidence:
 
Level of Evidence:
 
<span  
 
<span  
Line 18: Line 18:
 
border-style:solid;">Phase III</span>
 
border-style:solid;">Phase III</span>
  
−
*[[Ruxolitinib (Jakafi)]] 10-25 mg PO twice daily (''Multiple schedules were used in original publications, with maximum 25 mg PO twice daily'')
+
*[[Ruxolitinib (Jakafi)]] 10 to 25 mg PO twice per day
  
−
'''Continue as tolerated'''
+
'''given until progression'''
  
 
===References===
 
===References===
−
# Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. doi:10.1056/NEJMoa1002028. [http://www.nejm.org/doi/full/10.1056/NEJMoa1002028 link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20843246 PubMed]
+
# Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. doi:10.1056/NEJMoa1002028. [http://www.nejm.org/doi/full/10.1056/NEJMoa1002028 link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1002028/suppl_file/nejmoa1002028_appendix.pdf supplementary appendix] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20843246 PubMed]
−
# Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98. doi:10.1056/NEJMoa1110556. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110556#t=article link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375970 PubMed]
+
# Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98. doi:10.1056/NEJMoa1110556. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110556#t=article link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375970 PubMed] content property of [http://hemonc.org HemOnc.org]
−
# Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. doi:10.1056/NEJMoa1110557. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110557#t=article link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375971 PubMed]
+
# Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. doi:10.1056/NEJMoa1110557. [http://www.nejm.org/doi/full/10.1056/NEJMoa1110557#t=article link to original article] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_appendix.pdf supplementary appendix] [http://www.nejm.org/doi/suppl/10.1056/NEJMoa1110557/suppl_file/nejmoa1110557_protocol.pdf trial protocol] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22375971 PubMed]

Revision as of 03:29, 15 September 2013

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.


Ruxolitinib (Jakafi)

Regimen, Verstovsek, et al. 2010; Harrison, et al. 2012 (COMFORT-II); Verstovsek, et al. 2012 (COMFORT-I)

COMFORT: COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment

Level of Evidence: Phase III

given until progression

References

  1. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep 16;363(12):1117-27. doi:10.1056/NEJMoa1002028. link to original article supplementary appendix contains verified protocol PubMed
  2. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787-98. doi:10.1056/NEJMoa1110556. link to original article contains verified protocol PubMed content property of HemOnc.org
  3. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799-807. doi:10.1056/NEJMoa1110557. link to original article supplementary appendix trial protocol contains verified protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Myelofibrosis&oldid=3788"